羟氯喹与氯喹相关心血管不良事件:COVID-19前报告的全面药物警戒分析
基于FAERS数据库(2014年7月至2019年9月)对羟氯喹/氯喹进行不成比例分析,共识别4895例相关不良事件报告,其中696例(14.2%)为心血管不良事件。与全库相比,羟氯喹/氯喹与心肌病、QT间期延长、心律失常和心力衰竭的报告率升高相关,且这些心血管不良事件伴随较高的住院率和死亡率。
要点
- 羟氯喹/氯喹相关心血管不良事件以心肌病报告比值比最高(ROR=29.0)。
- QT间期延长、心律失常和心力衰竭的报告率亦显著升高。
- 此类心血管不良事件伴随39%住院率和8%死亡率,用药前应评估心脏状况。
核心结论
- 在真实世界数据中,羟氯喹/氯喹治疗与多种心血管不良事件的较高报告率相关,尤其是心肌病、QT间期延长、心律失常和心力衰竭。
- 羟氯喹/氯喹相关心血管不良事件导致较高的严重结局发生率,作为超说明书用药时应审慎考虑,尤其对心脏病患者。
研究设计与样本
- 研究基于美国FDA不良事件报告系统(FAERS)数据库2014年7月至2019年9月的数据,对羟氯喹/氯喹进行不成比例分析。
- 分析采用报告比值比(ROR)和信息成分95%可信区间下限(IC025)。
- 全库包含6 677 225份报告,平均年龄53(±17)岁,74%为女性。
主要发现
- 共识别4895例羟氯喹/氯喹相关不良事件报告,其中696例(14.2%)为心血管不良事件。
- 心肌病86例(1.8%),ROR=29.0(23.3-35.9);QT间期延长43例(0.9%),ROR=4.5(3.3-6.1);心律失常117例(2.4%),ROR=2.2(1.8-2.7);心力衰竭136例(2.8%),ROR=2.2(1.9-2.7),所有IC₀₂₅>0。
- 性别和年龄组间未观察到统计学显著差异。
- 心血管不良事件在系统性红斑狼疮和干燥综合征患者中报告更频繁。
- 羟氯喹/氯喹相关心血管不良事件伴随的住院率和死亡率分别为39%和8%;过量报告中QT间期延长和室性心律失常频率增加(分别为35%和25%)。
临床怎么用
- 临床使用羟氯喹/氯喹时应关注心血管不良事件风险,尤其对已有心脏疾病患者。
- 超说明书使用羟氯喹/氯喹时需权衡心血管风险,并加强心电图等心脏监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: There is a clinical need for safety data regarding hydroxychloroquine (HCQ) and chloroquine (CQ) during the coronavirus (COVID-19) pandemic. We analysed real-world data using the U.S. Food and Drug Administration Adverse Events Reporting System (FAERS) database to assess HCQ/CQ-associated cardiovascular adverse events (CVAEs) in pre-COVID-19 reports. METHODS: We conducted disproportionality analysis of HCQ/CQ in the FAERS database (07/2014-9/2019), using reporting odds ratio (ROR) and the lower bound of the information component 95% credibility interval (IC025 ). RESULTS: The full database contained 6 677 225 reports with a mean (±SD) age of 53 (±17) years and 74% females. We identified 4895 reports of HCQ/CQ related adverse events, of which 696 (14.2%) were CVAEs. Compared with the full database, HCQ/CQ use was associated with a higher reporting rate of major CVAEs, including cardiomyopathy (n = 86 [1.8%], ROR = 29.0 [23.3-35.9]), QT prolongation (n = 43 [0.9%], ROR = 4.5 [3.3-6.1]), cardiac arrhythmias (n = 117 [2.4%], ROR = 2.2 [1.8-2.7]) and heart failure (n = 136 [2.8%], ROR = 2.2 [1.9-2.7], all IC₀₂₅ > 0). No statistically significant differences were observed between sex and age groups. CVAEs were reported more often in patients with systemic lupus erythematosus and Sjogren's syndrome. HCQ/CQ-associated CVAEs demonstrated subsequent hospitalization and mortality rates of 39% and 8%, respectively. Overdose reports demonstrated an increased frequency of QT prolongation and ventricular arrhythmias (35% and 25%, respectively). CONCLUSION: In a real-world setting, HCQ/CQ treatment is associated with higher reporting rates of various CVAEs, particularly cardiomyopathy, QT prolongation, cardiac arrhythmias and heart failure. HCQ/CQ-associated CVAEs result in high rates of severe outcomes and should be carefully considered as an off-label indication, especially for patients with cardiac disorders.
引用
- Goldman A, Bomze D, Dankner R, et al. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. Br J Clin Pharmacol. 2020. PMID: 32964535. doi:10.1111/bcp.14546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。